Unlike single-agent therapy, the simultaneous inhibition of TIM3 and PD1 has been shown to reinstate effector T cell functionality, induce more significant tumor shrinkage, and amplify the anti-tumor immune response (Figure 6) (149). This evidence concerns the gene HAVCR2 and neoplasm.